Besides, with the small sample size of our RA patients, among whom the number of moderate-to-severe NAFLD cases was low, we could not provide a ROC-derived cut-off value of serum Gal-9 for predicting moderate-to-severe NAFLD. The gene discussed is LGALS9; the disease is metabolic dysfunction-associated steatotic liver disease.